Digital Commons Network^™

First Episode Is The Best Episode: Lessons And Limitations In Duration Of Untreated Psychosis (Dup) And Outcome In Schizophrenia, Amresh Srivastava

Amresh Srivastava

First episode is the best episode: Lessons and limitations in duration of untreated psychosis (DUP) and outcom Amresh Shrivastavaa, *, Nilesh Shahb, Meghana Thakarc, Larry Stittd, Gurusamy Chinnasamye

a Executive Director , Mental Health Foundation of India (PRERANA Charitable trust) and Silver Mind Hospital, 209 Shivkripa Complex, Gokhale Road, Thane, Mumbai, Maharashtra, India 400 602, Currently: Assistant Professor of Psychiatry, The University of western Ontario, & associate Scientist, Lawson Health Research Institute, London, Ontario, Canada, E Mail : amresh.edu@gmail.com Professor of Psychiatry LTMG Hospital, University of Mumbai, Sion, Mumbai, Maharashtra, India 400 022 c Clinical psychologist, Silver Mind Hospital, Mumbai, …

Response, Remission & Recovery: Need To Review Outcome Measures For Schizophrenia, Amresh Shrivastava, Nilesh Shah

Amresh Srivastava

Schizophrenia is a complex neurobehavioral disorder known to be associated with poor outcome. It causes significant disability in patients and burden of care amongst relatives. Outcome in developing countries has been reported to be far better than western world, which has come into scientific scanner recently. Wide gap exists between expectations of outcome amongst patients, relatives, caregivers and professionals, which is possibly because of limitations in measurements tools. Significant number of patients remain marginalized without improvement in social & occupational functioning preventing their integration into mainstream of society despite 'clinically reported good outcome' and significant advancement in treatments. The contemporary …

Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava

Amresh Srivastava

No abstract provided.

Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava

Amresh Srivastava

No abstract provided.

Schizophrenia: General Findings And Current Status, Amresh Srivastava

Amresh Srivastava

No abstract provided.

Schizophrenia: General Findings And Current Status, Amresh Srivastava

Amresh Srivastava

No abstract provided.

Relapse Prevention In Schizophrenia, Amresh Srivastava

Amresh Srivastava

No abstract provided.

Outcome In Schizophrenia: The Long-Term Good Outcome In Schizophrenia Is Not Yet Good Enough, Amresh Srivastava, Meghan Thakar

Amresh Srivastava

The illness of schizophrenia has always been a matter of concern for its nature and extent of outcome particularly for its regional and cultural differences. The concept of outcome has been evolving and this study examines the scenario of good outcome in developing countries.

Cognition As An Outcome Measure In Schizophrenia, Amresh Srivastava

Amresh Srivastava

No abstract provided.

Mood Symptoms As Comorbidity In Schizophrenia, Amresh Srivastava

Amresh Srivastava

No abstract provided.

Differential Characteristics Of “Good Outcome Schizophrenia” In A Long-Term Ten Years Study, Mumbai, India, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt

Amresh Srivastava

No abstract provided.

Outcome In Schizophrenia: How Good Is "Good Outcome" Schizophrenia In Long-Term In Developing Countries, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt

Amresh Srivastava

No abstract provided.

Baseline Serum Prolactinin Drug Naïve First Episode Schizophrenia Predicts A Positive Clinical And Social Outcome At Five Years, Post Discharge Follow-Up, Amresh Srivastava, Manoj Tamhane, Meghana Thakar, Yves Bureau, Nilesh Shah

Amresh Srivastava

Serum prolactinis an indicator of tuberoinfundibulardopamine activity. It is reported to increase in wide variety of mental illnesses. It has close relationship with antipsychotic therapy. However, its relationship with psychopathology and outcome is not clear. Serum prolactinlevel was measured in 30 male and 30 female drug naive patients of schizophrenia. Subsequently, these patients were treated with antipsychotics. The severity of psychopathology at the baseline and subsequent improvement at the end of 3 weeks and 6 weeks was assessed on modified brief psychiatric rating scale (mBPRS). Available to follow up at five years 18 males & 22 females patients were reassessed …

Atypical Antipsychotics And Cognitive Enhancement In Schizophrenia: The Current Status, Amresh Srivastava

Amresh Srivastava

No abstract provided.

Interface Of Cannabis And Early Psychosis--Priorities In Research And Service Development, Amresh Srivastava

Amresh Srivastava

Introduction: cannabis continues to affect mental health. Its abuse is on rise globally. In Canada a rise by 30% in last ten years has been observed in high school students. Interrelationship of cannabis with psychosis and schizophrenia is a complex one. Cannabis is highly comorbid with psychosis, & related to functional disability and outcome. It poses several challenges in understanding causal relationship for comorbidity, underlying neurochemical basis and specifics of service development. Prevalence of Cannabis varies from 20 to 50% early psychosis. Objective of this paper is to review available literature to identify challenges for newer targets of research and …

Identifying Schizophrenia: Paradigm Shift ‘The Uhr Research’, Amresh Srivastava

Amresh Srivastava

No abstract provided.

Perspectives In Social Outcome Of Schizophrenia, Amresh Shrivastava

Amresh Srivastava

No abstract provided.

Stigma And Discrimination: The Mumbai Experience, Amresh Srivastava

Amresh Srivastava

Title: Stigma & Discrimination: The Mumbai Experience

Main Author: Amresh Shrivastava MD, DPM, MRCPsych, University of Western Ontario, London, Ontario, Canada.

Co-Authors: Gopa Sarkhel, MA, Iyer Sunita MA, Thakar Meghana MA, Shah Nilesh, MD, DPM

Address of Presenter: Executive Director, Mental health foundation of India (PRERANA Charitable Trust) Mumbai, India; Currently at Department of Psychiatry, The University of Western Ontario, London, Ontario, Canada Address: Regional mental health care, 467 Sunset Drive, St. Thomas, N5N 3V9, St. Thomas, Ontario, Canada Phone: 1-5196318510; Fax: 1-519-631-2512. E-mail: amresh.edu@gmail.com

Background: People with schizophrenia suffer from stigma and discrimination to a great extent, and this …

Stigma And Discrimination : Mumbai Experience, Amresh Srivastava

Amresh Srivastava

Title: Stigma & Discrimination: The Mumbai Experience Main Author: Amresh Shrivastava MD, DPM, MRCPsych, University of Western Ontario, London, Ontario, Canada. Co-Authors: Gopa Sarkhel, MA, Iyer Sunita MA, Thakar Meghana MA, Shah Nilesh, MD, DPM Address of Presenter: Executive Director, Mental health foundation of India (PRERANA Charitable Trust) Mumbai, India; Currently at Department of Psychiatry, The University of Western Ontario, London, Ontario, Canada Address: Regional mental health care, 467 Sunset Drive, St. Thomas, N5N 3V9, St. Thomas, Ontario, Canada Phone: 1-5196318510; Fax: 1-519-631-2512. E-mail: amresh.edu@gmail.com Background: People with schizophrenia suffer from stigma and discrimination to a great extent, and this …

Motivating Persons With Schizophrenia To Exercise: Rationale And Design, Lora Humphrey Beebe Phd, P Mhnp-Bc, Renee Burk, Kelly B. Mcintyre, Kathlene Smith, Dawn Velligan, Barbara Resnick, Abbas Tavakoli, Cliff Tennison, Olivera Dessieux

Lora Humphrey Beebe PhD, PMHNP-BC

Persons with schizophrenia spectrum disorders (SSDs) are not only at risk because of disabling disease symptoms but because necessary medications create health risks associated with high rates of obesity. Despite the well-known benefits of exercise, persons with SSDs rarely adhere to such regimens; few interventions to motivate exercise behavior have been tested in this group.

The purpose of this study is to examine effects of the Walk, Address sensations, Learn about exercise, Cue exercise behavior for persons with SSDs (WALC-S) motivational intervention upon exercise behavior. We will recruit a total of eighty outpatients 18–68 years, meeting these criteria: 1) chart …